Flynn James E — SEC Form 4 filings
SEC reporting owner CIK 1352546. 26 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2024-02-08 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 12 legs across 4 filings — 18,735,617 shares, $93,759,993 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 19 legs across 5 filings — 4,395,993 shares, $293,997,535 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 83.
- Largest priced transaction: sale of 1,000,000 shares @ $97.75 ($97,750,000) in Nuvalent, Inc., filed 2024-10-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Nuvalent, Inc. (NUVL) | Director, 10% owner | 6 | — | 4 legs · 2,742,574 sh · $266,374,975 | 27 |
| Larimar Therapeutics, Inc. (LRMR) | Director, 10% owner | 6 | 10 legs · 18,665,617 sh · $92,499,993 | — | 3 |
| ARS Pharmaceuticals, Inc. (SPRY) | 10% owner | 2 | — | 10 legs · 1,303,419 sh · $23,806,856 | — |
| AdaptHealth Corp. (AHCO) | 10% owner | 1 | — | 5 legs · 350,000 sh · $3,815,704 | — |
| Bicara Therapeutics Inc. (BCAX) | 10% owner | 1 | 2 legs · 70,000 sh · $1,260,000 | — | 4 |
| BiomX Inc. (PHGE) | Director | 7 | — | — | 24 |
| Parabilis Medicines, Inc. (PBLS) | 10% owner | 1 | — | — | 16 |
| Acutus Medical, Inc. (AFIB) | Director | 1 | — | — | 5 |
| Fractyl Health, Inc. (GUTS) | 10% owner | 1 | — | — | 4 |
Form 4 filings — Flynn James E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | Nuvalent, Inc. (NUVL) jointly with DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Mgmt HIF, L.P., Deerfield Healthcare Innovations Fund, L.P., DEERFIELD PARTNERS, L.P., Deerfield Mgmt L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P. | Disposition to issuer (D): 8,299,225 @ $124 · Disposition to issuer (D): 8,299,225 @ $124 · Disposition to issuer (D): 650,000 @ $124 · Code (U): 5,146 @ $124 · Code (U): 5,146 @ $124 · Disposition to issuer (D): 3,444 @ $124 · +12 more | EDGAR |
| 2026-06-18 | 4 | Nuvalent, Inc. (NUVL) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. | Grant/award (A): 3,444 @ $0 | EDGAR |
| 2026-06-11 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with Deerfield Mgmt HIF, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P. | Conversion (C): 122,990 · Conversion (C): 122,990 · Conversion (C): 149,238 · Conversion (C): 149,238 · Conversion (C): 260,992 · Conversion (C): 260,992 · +10 more | EDGAR |
| 2026-05-20 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. | Grant/award (A): 55,150 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., DEERFIELD PARTNERS, L.P. | Purchase (P): 1,084,010 @ $5 · Purchase (P): 1,084,012 @ $5 · Purchase (P): 831,978 @ $5 · Purchase (P): 2,000,000 @ $5 | EDGAR |
| 2025-11-24 | 4 | Nuvalent, Inc. (NUVL) jointly with DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Mgmt HIF, L.P., Deerfield Healthcare Innovations Fund, L.P., DEERFIELD PARTNERS, L.P., Deerfield Mgmt L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P. | Sale (S): 371,287 @ $95.44 · Sale (S): 371,287 @ $95.44 | EDGAR |
| 2025-08-04 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., DEERFIELD PARTNERS, L.P. | Purchase (P): 3,387,529 @ $3.20 · Purchase (P): 3,387,539 @ $3.20 · Purchase (P): 2,599,932 @ $3.20 | EDGAR |
| 2025-07-01 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P. | Sale (S): 370,075 @ $18.46 · Sale (S): 370,074 @ $18.46 | EDGAR |
| 2025-06-20 | 4 | Nuvalent, Inc. (NUVL) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Grant/award (A): 2,647 @ $0 · Grant/award (A): 2,647 @ $0 · Grant/award (A): 4,147 (derivative) @ $0 · Grant/award (A): 4,147 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-04-23 | 4 | BiomX Inc. (PHGE) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt V, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P. | Grant/award (A): 1,611,864 (derivative) · Grant/award (A): 1,611,864 (derivative) | EDGAR |
| 2025-04-18 | 4 | BiomX Inc. (PHGE) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | BiomX Inc. (PHGE) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt V, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P. | Option exercise (M): 353,249 @ $0.93 · Option exercise (M): 353,249 @ $0.93 · Option exercise (M): 1,611,863 (derivative) · Option exercise (M): 1,611,863 (derivative) · Grant/award (A): 1,258,614 (derivative) · Grant/award (A): 1,258,614 (derivative) | EDGAR |
| 2025-01-28 | 4 | Acutus Medical, Inc. (AFIB) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Disposition to issuer (D): 1,889,509 (derivative) · Disposition to issuer (D): 1,889,509 (derivative) · Disposition to issuer (D): 209,996 (derivative) · Disposition to issuer (D): 193,002 (derivative) · Disposition to issuer (D): 31,116 (derivative) | EDGAR |
| 2024-11-13 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P. | Sale (S): 40,596 @ $17.45 · Sale (S): 40,596 @ $17.45 · Sale (S): 223,632 @ $18.15 · Sale (S): 223,632 @ $18.15 · Sale (S): 7,853 @ $17.16 · Sale (S): 7,854 @ $17.16 · +2 more | EDGAR |
| 2024-10-24 | 4 | Nuvalent, Inc. (NUVL) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt HIF, L.P., Deerfield Healthcare Innovations Fund, L.P., DEERFIELD PARTNERS, L.P., Deerfield Mgmt L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P. | Sale (S): 1,000,000 @ $97.75 · Sale (S): 1,000,000 @ $97.75 | EDGAR |
| 2024-09-17 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt V, L.P., Deerfield Private Design Fund V, L.P., DEERFIELD PARTNERS, L.P., Deerfield Mgmt L.P. | Conversion (C): 862,587 · Conversion (C): 862,587 · Purchase (P): 35,000 @ $18 · Purchase (P): 35,000 @ $18 · Conversion (C): 7,973,325 (derivative) · Conversion (C): 7,973,325 (derivative) | EDGAR |
| 2024-07-17 | 4 | BiomX Inc. (PHGE) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt V, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P. | Option exercise (M): 5,883,000 · Option exercise (M): 5,883,000 · Option exercise (M): 5,883 (derivative) · Option exercise (M): 5,883 (derivative) | EDGAR |
| 2024-07-15 | 4 | BiomX Inc. (PHGE) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Grant/award (A): 264,000 (derivative) @ $0 | EDGAR |
| 2024-07-11 | 4 | BiomX Inc. (PHGE) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt V, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P. | Grant/award (A): 722,175 (derivative) · Grant/award (A): 722,175 (derivative) · Grant/award (A): 20,175,000 (derivative) · Grant/award (A): 20,175,000 (derivative) | EDGAR |
| 2024-06-14 | 4 | Nuvalent, Inc. (NUVL) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Grant/award (A): 2,499 @ $0 · Grant/award (A): 2,499 @ $0 · Grant/award (A): 3,789 (derivative) @ $0 · Grant/award (A): 3,789 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | BiomX Inc. (PHGE) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt V, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P. | Grant/award (A): 3,055,049 · Grant/award (A): 3,055,049 · Grant/award (A): 13,490 (derivative) · Grant/award (A): 13,490 (derivative) · Grant/award (A): 40,350 (derivative) · Grant/award (A): 40,350 (derivative) | EDGAR |
| 2024-03-12 | 4 | AdaptHealth Corp. (AHCO) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt IV, L.P., DEERFIELD PARTNERS, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt L.P. | Sale (S): 47,992 @ $10.92 · Sale (S): 4,495 @ $11.03 · Sale (S): 94,567 @ $10.92 · Sale (S): 88,040 @ $11.13 · Sale (S): 114,906 @ $10.70 | EDGAR |
| 2024-02-16 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., DEERFIELD PARTNERS, L.P. | Purchase (P): 1,430,206 @ $8.74 · Purchase (P): 1,430,206 @ $8.74 · Purchase (P): 1,430,205 @ $8.74 | EDGAR |
| 2024-02-08 | 4 | Fractyl Health, Inc. (GUTS) jointly with Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Conversion (C): 757,548 · Conversion (C): 76,706 · Conversion (C): 1,625,699 (derivative) · Conversion (C): 164,612 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1352546 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →